 | • レポートコード：STR-DC038 • 出版社/出版日：Straits Research / 2019年11月28日 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：製薬 |
| Single User（1名様用、印刷不可） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Multi User（5名様用） | ￥836,200 (USD5,650) | ▷ お問い合わせ |
| Enterprise Price（法人閲覧用） | ￥1,073,000 (USD7,250) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートでは、プロカルシトニンの世界市場について調査・分析し、調査手法、市場概要、用途別（医療用、研究用）分析、地域別分析、企業概要などを含め次の構成でお届け致します。 ・イントロダクション ・調査手法 ・市場概要 ・プロカルシトニンの世界市場：用途別（医療用、研究用） ・プロカルシトニンの世界市場：地域別 ・企業概要 |
Global procalcitonin market was valued at USD 118.7 million in 2018, growing at a CAGR of 14.9% during the forecast period of 2019–2026.
The use of procalcitonin as a biomarker for the diagnosis of systemic infections and sepsis has significantly increased in the past few years. Overuse of antibiotics has increased the risk of antibiotic resistance. The Centers for Disease Control and Prevention (CDC) has estimated that about 2 million people get antibiotic-resistant infections in the U.S., out of which at least 23,000 people die every year. This has put a burden in terms of treatment cost and necessity of better diagnostic tools such as biomarkers. Procalcitonin (PCT), one of the blood biomarkers, is used at the different clinical stages and infections such as early detection of sepsis and therapy monitoring for respiratory infections. Identification of the bacterial origin of infection is the utmost important aspect of therapy. PCT can efficiently diagnose bacterial infection, especially in the case of hospital emergency and intensive care units. In addition, PCT-guided care is cost-effective, and it requires less hospital stay. For instance, on average it costs around USD 2,759 per PCT-treated patient. An economic study of PCT-guided antibiotic treatment of Acute Respiratory Infections has revealed that net savings can range from USD 73,326 in the ICU to more than USD 5 million in the outpatient clinic and ED setting; total savings could be more than USD 6 million.
Segmental Insights
For a better understanding of the global procalcitonin market, we have segmented the market by application.
By application, the market is segmented into medical and research. Medical application was valued at USD 7.74 million in 2018. The prevalence of sepsis has significantly increased in the last decade due to the aging population, increasing drug-resistance, and the rising number of more virulent pathogens. Additionally, malnutrition, poor sanitation, and lack of access to vaccines and timely treatments in the developing region have increased the overall incidence rate. It helps early diagnosis. It also helps in reducing the overuse of antibiotics in case of bronchitis and acquired pneumonia. For example, viruses cause acute bronchitis. However, 80% of patients are prescribed antibiotics and around 50% of antimicrobial use in the inpatient setting are not required. Hence, procalcitonin comes handy in determining the cause of infection without worsening the clinical outcomes.
Regional Insights
Global procalcitonin market by Americas, Asia Pacific, Europe, and the Middle East and Africa.
North America is dominating the market in the forecast period. Sepsis is a topmost condition to account for inpatient hospital expense in the U.S. Centers for Disease Control and Prevention (CDC) has estimated that each year around 1.7 million adults in America suffer from sepsis; nearly 270,000 Americans die, and 1 in 3 patients who die in a hospital have sepsis. It is a national epidemic and one of the largest unmet medical conditions responsible for almost half of the hospital deaths. It is also among the top five causes of hospitalization in adults. In the last decade, the treatment cost of sepsis has tripled to USD 27 billion. These factors have driven the overall demand for a comprehensive plan to treat sepsis and reduce the treatment cost. Moreover, Prevalence of the sepsis in the region is increasing rapidly. As per Canadian Sepsis Foundation, sepsis has been reported in 15% of all Intensive Care Unit (ICU) patients, and it is among 12 leading causes of death in Canada. Use of procalcitonin testing is an effective way of saving money by reducing the use of an unnecessary antibiotic. As per modeling study published in March 2015 by Clinical Chemistry and Laboratory Medicine, procalcitonin-guided care could save USD 700,000 as compared to usual care in 2014 in the U.S.
Europe is the second leading region in procalcitonin market. As per the U.K Sepsis Trust, sepsis kills 52,000 people and affects 25,000 children every year, 5 people die due to sepsis every hour in the U.K. In Germany, it is the third most common cause of death and claims 60,000 lives in a year. In addition, if the overall number of admissions for sepsis were reduced by 10%, 20%, or 30% then the annual cost savings can be 83 million euros, 166 million euros, or 249 million euros respectively. Adoption of guided antibiotic programs and procalcitonin test would help in providing better treatment of these indications.
Middle East and Africa are offering lucrative opportunities for the market. Sepsis is the major contributor to the global burden of diseases where low and middle-income countries witness a major number of cases and deaths from sepsis. This can be attributed to mortality, low awareness, poverty, and under-resourced public health care delivery systems. The International Journal of Infectious Diseases conducted a study in 2017 to examine the incidences of late-onset sepsis (LOS) in neonatal intensive care units (NICUs) in Arab states. The study was conducted for 2 years in five NICUs in Kuwait, Saudi Arabia, and the United Arab Emirates. LOS poses a major burden in these areas due to increasing care of premature babies. Procalcitonin tests will help in reducing mortality in these areas, hence, adoption will increase in future.
Key Players
Some of the prominent players in the market are Thermo Fisher Scientific, Diazyme, Roche Diagnostics, EKF Diagnostics Holdings plc, Siemens Healthcare Diagnostics Inc, Diasorin Inc, Biomerieux, Inc, Fujirebio Diagnostics, Inc and Abbott.
Competitive Landscape
Thermo Fisher Scientific has been a leader in the global procalcitonin testing market and it focuses on various distribution and licensing agreements with other companies to increase its market footprints. For instance, in 2012, the company partnered with Fujirebio Inc. to provide PCT in Japan. Moreover, Fujirebio Inc received FDA approval in 2018 for Lumipulse G B•R•A•H•M•S PCT Assay, increasing approvals are helping new entrants in unlocking procalcitonin market potential.
TABLE OF CONTENTS
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Market Overview
3.1 Report Segmentation & Scope
3.2 Value Chain Analysis: Procalcitonin Market
3.3 Key Market Trends
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitution
3.4.4 Threat of New Entrants
3.4.5 Competitive Rivalry
3.5 Market Share Analysis
4 Application Overview
4.1 Introduction
4.1.1 Market Size & Forecast
4.2 Medical Application
4.3 Research application
5 Regional Overview
5.1 Introduction
5.1.1 Market Size & Forecast
5.2 America
5.2.1 North America
5.2.1.1 U.S.
5.2.1.1.1 By Application
5.2.1.2 Canada
5.2.1.2.1 By Application
5.2.1.3 Mexico
5.2.1.3.1 By Application
5.2.2 South America
5.2.2.1 By Application
5.3 Europe
5.3.1 Market Size & Forecast (Value)
5.3.2 Western Europe
5.3.2.1 Germany
5.3.2.1.1 By Application
5.3.2.2 France
5.3.2.2.1 By Application
5.3.2.3 U.K.
5.3.2.3.1 By Application
5.3.2.4 Italy
5.3.2.4.1 By Application
5.3.2.5 Spain
5.3.2.5.1 By Application
5.3.2.6 Rest of Western Europe
5.3.2.6.1 By Application
5.3.3 Eastern Europe
5.4 Asia Pacific
5.4.1 Market Size & Forecast (Value)
5.4.2 China
5.4.2.1 By Application
5.4.3 India
5.4.3.1 By Application
5.4.4 Japan
5.4.4.1 By Application
5.4.5 South Korea
5.4.5.1 By Application
5.4.6 Australia
5.4.6.1 By Application
5.4.7 Rest of Asia-Pacific
5.4.7.1 By Application
5.5 Middle East
5.5.1 Market Size & Forecast (Value)
5.5.2 The Middle East
5.5.2.1 UAE
5.5.2.2.1 By Application
5.5.2.2 Qatar
5.5.2.2.1 By Application
5.5.2.3 Rest of Middle East
5.5.2.3.1 By Application
5.6 Africa
5.6.1 Market Size & Forecast (Value)
5.6.2 South Africa
5.6.2.1 South Africa
5.6.2.1.1 By Application
5.6.2.2 Ghana
5.6.2.2.1 By Application
5.6.2.3 Nigeria
5.6.2.3.1 By Application
5.6.2.4 Rest of Africa
5.6.2.4.1 By Application
6. Company Profile
6.1 Thermo Fisher Scientific
6.1.1 Company Overview
6.1.2 Financial Performance
6.1.3 Recent Developments
6.1.4 Product Portfolio
6.2 Diazyme
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Recent Developments
6.2.4 Product Portfolio
6.3 Roche Diagnostics
6.3.1 Company Overview
6.3.2 Financial Performance
6.3.3 Recent Developments
6.3.4 Product Portfolio
6.4 EKF Diagnostics Holdings plc
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Recent Developments
6.4.4 Product Portfolio
6.5 Siemens Healthcare Diagnostics Inc
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Recent Developments
6.5.4 Product Portfolio
6.6 Diasorin Inc
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Recent Developments
6.6.4 Product Portfolio
6.7 Fujirebio Diagnostics, Inc
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Recent Developments
6.7.4 Product Portfolio
6.8 Abbott
6.8.1 Company Overview
6.8.2 Financial Performance
6.8.3 Recent Developments
6.8.4 Product Portfolio
TABLE 1 Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 2 Medical Procalcitonin Market Share Market Share, By Region, 2016-2026 ($ Million)
TABLE 3 Research Procalcitonin Market Share, By Region, 2016-2026, ($ Million)
TABLE 4 Procalcitonin Market Share Value, 2016-2026 ($Million)
TABLE 5 Procalcitonin Market Share, By Region, 2016-2026 ($ Million)
TABLE 6 America Procalcitonin Market Share Value, By Region, 2016-2026 ($Million)
TABLE 7 America Procalcitonin Market Share value, By Application, 2016-2026 ($Million)
TABLE 8 U.S. Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 9 Canada Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 10 Mexico Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 11 South America Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 12 Europe Procalcitonin Market Share Value, By Region, 2016-2026 ($Million)
TABLE 13 Europe Procalcitonin Market Share, By Application2016-2026 ($Million)
TABLE 14 Western Europe Procalcitonin Market Share Value, By Country, 2016-2026 ($Million)
TABLE 15 Western Europe Procalcitonin Market Share, By Application2016-2026 ($Million)
TABLE 16 Germany Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 17 France Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 18 UK Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 19 Italy Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 20 Spain Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 21 Rest of Western Europe Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 22 Eastern Europe Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 23 Asia-Pacific Procalcitonin Market Share, By Country, 2016-2026 ($Million)
TABLE 24 Asia-Pacific Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 25 Japan Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 26 China Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 27 Australia Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 28 India Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 29 South Korea Procalcitonin Market Share, By Application2016-2026 ($Million)
TABLE 30 Rest of Asia-pacific Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 31 The Middle East and Africa Procalcitonin Market Share, By Region, 2016-2026 ($Million)
TABLE 32 The Middle East and Africa Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 33 The Middle East Procalcitonin Market Share, By Country, 2016-2026 ($Million)
TABLE 34 The Middle East Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 35 Saudi Arabia Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 36 UAE Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 37 Qatar Procalcitonin Market Share, By Application, 2016-2026 ($Million)
TABLE 38 Africa Procalcitonin Market Share, By Country, 2016-2026 ($Million)
TABLE 39 Africa Procalcitonin Market Share, By Application, 2016-2026 ($Million)
List of Figures
FIGURE 1 Procalcitonin Market Overview
FIGURE 2 Value Chain Analysis
FIGURE 3 Bargaining Power of Suppliers
FIGURE 4 Bargaining Power of Buyers
FIGURE 5 Threat of Substitutes
FIGURE 6 Threat of New Entrants
FIGURE 7 Competitive Rivalry
FIGURE 8 Procalcitonin Market, 2016-2026
FIGURE 9 U.S. Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 10 Canada Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 11 Mexico Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 12 South America Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 13 Western Europe Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 14 Germany Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 15 France Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 16 UK Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 17 Italy Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 18 Spain Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 19 Rest of Western Europe Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 20 Eastern Europe Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 21 Japan Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 22 China Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 23 Australia Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 24 India Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 25 South Korea Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 26 Rest of Asia-pacific Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 27 The Middle East Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 28 Saudi Arabia Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 29 UAE Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 30 Qatar Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 31 Rest of The Middle East Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 32 Africa Procalcitonin Market Share, 2016-2026 ($Million)
FIGURE 33 Thermo Fisher Scientific: Revenue Analysis, ($ million)
FIGURE 34 Thermo Fisher Scientific: Segment Revenue 2018 (%)